DWM
CRSP icon

Dakota Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Dakota Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,487
Closed -$273K – 579
2022
Q2 		$273K Buy
+4,487
New +$264K 0.03% 389

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dakota Wealth Management's CRSP Position: Q3 2022 in Review

Dakota Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 4,487 shares — an estimated $273K sold.

Dakota Wealth Management first reported a position in CRSP in Q2 2022 and held it in 1 quarter. The position peaked at $273K in Q2 2022. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

  • Dakota Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Dakota Wealth Management sold 4,487 CRISPR Therapeutics shares in Q3 2022, an estimated $273K.
  • Dakota Wealth Management first reported a position in CRISPR Therapeutics in Q2 2022 and held it in 1 quarter.
  • Dakota Wealth Management's CRISPR Therapeutics position peaked at $273K in Q2 2022.
  • 436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Dakota Wealth Management's 13F filing for Q3 2022, filed 10 Nov 2022.